FY2024 Earnings Forecast for KYTX Issued By Leerink Partnrs

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Equities researchers at Leerink Partnrs raised their FY2024 earnings estimates for shares of Kyverna Therapeutics in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($3.33) for the year, up from their prior estimate of ($3.54). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.31) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics’ Q4 2024 earnings at ($0.87) EPS, FY2025 earnings at ($4.35) EPS, FY2026 earnings at ($4.73) EPS, FY2027 earnings at ($5.68) EPS and FY2028 earnings at ($6.03) EPS.

Other analysts have also recently issued reports about the stock. Rodman & Renshaw assumed coverage on shares of Kyverna Therapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $16.00 target price for the company. HC Wainwright reiterated a “neutral” rating and issued a $7.00 target price on shares of Kyverna Therapeutics in a research note on Thursday, September 19th. UBS Group assumed coverage on shares of Kyverna Therapeutics in a research note on Thursday, October 10th. They issued a “buy” rating and a $13.00 target price for the company. JPMorgan Chase & Co. reduced their price target on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Finally, RODMAN&RENSHAW raised shares of Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $25.86.

Kyverna Therapeutics Trading Down 7.4 %

KYTX stock opened at $4.08 on Monday. The firm has a 50 day moving average of $5.40 and a 200 day moving average of $8.34. Kyverna Therapeutics has a 52 week low of $3.94 and a 52 week high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its earnings results on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.01. The company had revenue of $0.01 million during the quarter.

Hedge Funds Weigh In On Kyverna Therapeutics

Several institutional investors have recently made changes to their positions in the company. Bain Capital Life Sciences Investors LLC purchased a new position in shares of Kyverna Therapeutics during the 1st quarter valued at approximately $78,590,000. Deerfield Management Company L.P. Series C increased its holdings in shares of Kyverna Therapeutics by 35.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company’s stock valued at $14,872,000 after purchasing an additional 520,663 shares in the last quarter. Novo Holdings A S increased its holdings in shares of Kyverna Therapeutics by 5.7% during the 3rd quarter. Novo Holdings A S now owns 1,850,000 shares of the company’s stock valued at $9,046,000 after purchasing an additional 100,000 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Kyverna Therapeutics during the 1st quarter valued at approximately $23,093,000. Finally, Millennium Management LLC increased its holdings in shares of Kyverna Therapeutics by 32.8% during the 2nd quarter. Millennium Management LLC now owns 923,082 shares of the company’s stock valued at $6,923,000 after purchasing an additional 227,988 shares in the last quarter. 18.08% of the stock is owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.